Eleven reports first efficacy data for dry eye compound

Eleven Biotherapeutics Inc. (Cambridge, Mass.) said thrice-daily topical EBI-005 for six weeks significantly improved signs and symptoms of dry eye disease compared to baseline in a 74-patient Phase I...